Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Infectio ; 26(4):441-449, 2022.
Article in English | EMBASE | ID: covidwho-2205092

ABSTRACT

The vaccination against SARS-CoV-2 has been recognized as a priority strategy to safeguard public health. However, disparities in productive, acquisitive and distributional capacity have led to delays in immunization, particularly in low- and middle-income countries. Consequently, global coverage is expected to achieve herd immunity against COVID-19 by 2023 or 2024, although with highly variable coverage percentages among countries. In Latin America, immunization against COVID-19 faces different challenges to achieve herd immunity. To date (February 6, 2022), the countries that had several doses needed to immunize their populations with at least two doses (number of doses between population) were Peru (520.7%), Chile (458.4%), Argentina (298.0%), Brazil (236.6%), Bolivia (206.0%) and Uruguay (unconfirmed doses). On the other hand, Uruguay (210.7%) and Chile (238.3%) have applied twice as many doses as their populations. Argentina (194.3%), Brazil (173.6%), Ecuador (170.3%), Peru (170.3%), Costa Rica (161.1%), and Panama (153.5%) are on the way to achieving this goal. In addition, Latin American countries also showed an insufficient distribution of vaccines and a storage capacity limited to only a few cities and multiple frequencies of vaccine hesitancy. Due to these scenarios, the production of more vaccine doses and equitable distribution to the rest of the population within the Latin American region should remain a public health priority to achieve collective immunity in the shortest time possible. Copyright © 2022 Asociacion Colombiana de Infectologia. All rights reserved.

2.
Egyptian Journal of Radiology and Nuclear Medicine ; 51(1), 2020.
Article in English | EMBASE | ID: covidwho-901949

ABSTRACT

Background: The tomographic findings in COVID-19, its classification, a brief overview of the application of artificial intelligence, and the stages during the course of the disease in patients with moderate COVID-19 Main body: Chest CT allows us to follow the course of COVID-19 in an objective way;each phase has characteristic imaging findings and, consequently, takes the corresponding measures. A search was made in the PubMed database with the keywords extracted from the DeCs and the combinations of these. Only articles published between December 2019 and June 2020 were included. The search was limited to the English language. Conclusions: CT serves to monitor the course of the disease since it assesses the severity of lung involvement. The most frequent finding is bilateral ground glass opacities with a subpleural distribution. The progression occurs in two phases: one slow and one fast. At discharge, the patient may have ground glass opacities or areas that will later become fibrosis, leaving sequelae for life.

SELECTION OF CITATIONS
SEARCH DETAIL